Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.31
(2.67%)
CNY 2.31
(2.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 240.58 Million CNY | -42.12% |
| 2022 | 415.63 Million CNY | -20.34% |
| 2021 | 521.73 Million CNY | -3.86% |
| 2020 | 542.69 Million CNY | -23.69% |
| 2019 | 711.15 Million CNY | -15.35% |
| 2018 | 840.12 Million CNY | -19.76% |
| 2017 | 1.04 Billion CNY | -11.11% |
| 2016 | 1.17 Billion CNY | 32.65% |
| 2015 | 887.93 Million CNY | 52.77% |
| 2014 | 581.21 Million CNY | 59.87% |
| 2013 | 363.55 Million CNY | 20.17% |
| 2012 | 302.54 Million CNY | 21.67% |
| 2011 | 248.65 Million CNY | 68.13% |
| 2010 | 147.89 Million CNY | 152.62% |
| 2009 | 58.54 Million CNY | 42.2% |
| 2008 | 41.17 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 75.62 Million CNY | -28.88% |
| 2024 Q1 | 77.92 Million CNY | 3321.27% |
| 2024 Q2 | 106.32 Million CNY | 36.45% |
| 2023 Q2 | 140.79 Million CNY | 13.62% |
| 2023 Q1 | 123.92 Million CNY | 11.0% |
| 2023 Q3 | 89.13 Million CNY | -36.69% |
| 2023 Q4 | -2.41 Million CNY | -102.71% |
| 2023 FY | 240.58 Million CNY | -42.12% |
| 2022 Q3 | 88.71 Million CNY | -16.76% |
| 2022 Q1 | 108.69 Million CNY | 191.68% |
| 2022 FY | 415.63 Million CNY | -20.34% |
| 2022 Q4 | 111.64 Million CNY | 25.84% |
| 2022 Q2 | 106.58 Million CNY | -1.94% |
| 2021 FY | 521.73 Million CNY | -3.86% |
| 2021 Q4 | 37.26 Million CNY | -78.36% |
| 2021 Q2 | 169.13 Million CNY | 18.17% |
| 2021 Q3 | 172.21 Million CNY | 1.82% |
| 2021 Q1 | 143.12 Million CNY | -11.85% |
| 2020 FY | 542.69 Million CNY | -23.69% |
| 2020 Q1 | 104.64 Million CNY | -42.71% |
| 2020 Q2 | 155.4 Million CNY | 48.51% |
| 2020 Q3 | 120.29 Million CNY | -22.59% |
| 2020 Q4 | 162.35 Million CNY | 34.97% |
| 2019 Q3 | 146.38 Million CNY | -7.9% |
| 2019 Q4 | 182.64 Million CNY | 24.77% |
| 2019 Q2 | 158.93 Million CNY | -28.79% |
| 2019 Q1 | 223.18 Million CNY | 28.72% |
| 2019 FY | 711.15 Million CNY | -15.35% |
| 2018 Q2 | 242.81 Million CNY | 4.6% |
| 2018 Q4 | 173.38 Million CNY | -9.59% |
| 2018 FY | 840.12 Million CNY | -19.76% |
| 2018 Q1 | 232.13 Million CNY | 14.2% |
| 2018 Q3 | 191.77 Million CNY | -21.02% |
| 2017 Q2 | 302.39 Million CNY | 3.49% |
| 2017 FY | 1.04 Billion CNY | -11.11% |
| 2017 Q3 | 249.11 Million CNY | -17.62% |
| 2017 Q4 | 203.28 Million CNY | -18.4% |
| 2017 Q1 | 292.19 Million CNY | 31.92% |
| 2016 FY | 1.17 Billion CNY | 32.65% |
| 2016 Q3 | 284.63 Million CNY | -36.21% |
| 2016 Q2 | 446.18 Million CNY | 97.8% |
| 2016 Q4 | 221.48 Million CNY | -22.19% |
| 2016 Q1 | 225.57 Million CNY | -3.13% |
| 2015 Q1 | 146.16 Million CNY | -29.59% |
| 2015 Q4 | 232.85 Million CNY | 8.58% |
| 2015 Q3 | 214.44 Million CNY | -27.18% |
| 2015 Q2 | 294.47 Million CNY | 101.46% |
| 2015 FY | 887.93 Million CNY | 52.77% |
| 2014 Q2 | 146.65 Million CNY | 38.51% |
| 2014 Q3 | 121.07 Million CNY | -17.44% |
| 2014 Q4 | 207.59 Million CNY | 71.45% |
| 2014 FY | 581.21 Million CNY | 59.87% |
| 2014 Q1 | 105.88 Million CNY | -8.49% |
| 2013 Q2 | 92.86 Million CNY | 36.82% |
| 2013 Q3 | 87.11 Million CNY | -6.19% |
| 2013 Q4 | 115.7 Million CNY | 32.82% |
| 2013 FY | 363.55 Million CNY | 20.17% |
| 2013 Q1 | 67.87 Million CNY | -18.35% |
| 2012 Q3 | 69.13 Million CNY | -16.58% |
| 2012 Q2 | 82.87 Million CNY | 22.97% |
| 2012 FY | 302.54 Million CNY | 21.67% |
| 2012 Q1 | 67.39 Million CNY | 4.88% |
| 2012 Q4 | 83.12 Million CNY | 20.23% |
| 2011 Q1 | 43.9 Million CNY | -38.0% |
| 2011 Q2 | 77.32 Million CNY | 76.12% |
| 2011 Q4 | 64.26 Million CNY | 1.74% |
| 2011 Q3 | 63.16 Million CNY | -18.32% |
| 2011 FY | 248.65 Million CNY | 68.13% |
| 2010 FY | 147.89 Million CNY | 152.62% |
| 2010 Q4 | 70.81 Million CNY | 77.48% |
| 2010 Q3 | 39.89 Million CNY | 0.0% |
| 2009 FY | 58.54 Million CNY | 42.2% |
| 2008 FY | 41.17 Million CNY | 0.0% |